GOB-1

........10........20........30........40........50........60........70........80........90.......100.......110.......120.......130.......140.......150.......160.......170.......180.......190.......200.......210.......220.......230.......240.......250.......260.......270.......280.......... MRNFATLFFMFICLGLNAQVVKEPENMPKEWNQAYEPFRIAGNLYYVGTYDLASYLIVTDKGNILINTGTAESLPIIKANIQKLGFNYKDIKILLLTQAHYDHTGALQDFKTETAAKFYADKADVDVLRTGGKSDYEMGKYGVTFKPVTPDKTLKDQDKIKLGNITLTLLHHPGHTKGSCSFIFETKDEKRKYRVLIANMPSVIVDKKFSEVTAYPNIQSDYAYTFGVMKKLDFDIWVASHASQFDLHEKRKEGDPYNPQLFMDKQSYFQNLNDLEKSYLDKIKKDSQDK

GOB-18	................S........................................................F.............................................V................................................................................................................................................................N.........	98.62 %
GOB-24	...........................................................G.............................G.............................V................................................................................................................................................................N.........	98.62 %
GOB-28	.........................................................................................G..................................A..........................N........T.......................................................................................................................N.........	98.28 %
GOB-30	.........................................................................F.............................................V................................................................................................................................................................N.........	98.97 %
GOB-40	.........................................................................FS.............................................................................................................................................................................................................N.........	98.97 %
GOB-41	............................................................................................................................A..........................N........T.......................................................................................................................N.........	98.62 %
GOB-43	............................................................................................................................A...K.......................................................................................................................................................N.........	98.97 %
GOB-45	........................................................................................................................................................................................................................................................................................N.........	99.66 %
GOB-53	............................................................................................................................A.......E...............................T.............................................................................................................................	98.97 %
GOB-P1	---------------------.......N.................L..................................................................................................................................................................................................................................-----------------	86.21 %

Last updated: November 20, 2024.

If you use BLDB please cite: Naas, T.; Oueslati, S.; Bonnin, R. A.; Dabos, M. L.; Zavala, A.; Dortet, L.; Retailleau, P.; Iorga, B. I., Beta-Lactamase DataBase (BLDB) – Structure and Function. J. Enzyme Inhib. Med. Chem. 2017, 32, 917-919.

The development of the BLDB database was funded in part by the JPIAMR transnational project DesInMBL, the Région Ile-de-France (DIM Malinf) and the Laboratory of Excellence in Research on Medication and Innovative Therapeutics (LERMIT).

Contact: contact@bldb.eu

Live statistics (since December 3rd, 2023)